help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Esposito, D. L.
Right arrow Articles by LeRoith, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Esposito, D. L.
Right arrow Articles by LeRoith, D.
Endocrinology Vol. 138, No. 7 2979-2988
Copyright © 1997 by The Endocrine Society

ARTICLES

Tyrosine Residues in the C-Terminal Domain of the Insulin-Like Growth Factor-I Receptor Mediate Mitogenic and Tumorigenic Signals*

Diana L. Esposito1, Vicky A. Blakesley, Anatolii P. Koval, Angus G. Scrimgeour and Derek LeRoith

Diabetes Branch, NIDDK, NIH, Bethesda, Maryland 20892-1770

Address all correspondence and requests for reprints to: Derek LeRoith, DB/NIDDK/NIH, Building 10, Room 8S235A, 10 Center Dr MSC 1770, Bethesda, Maryland 20892-1770. E-mail:derek{at}helix.nih.gov

We investigated cellular proliferation, the transforming activity, and activation of known signal transduction pathways in NIH-3T3 cells stably expressing insulin-like growth factor-I receptors (IGF-IRs) with amino acid substitutions in the carboxy(C)-terminal domain. The mutant receptors contained substitutions of both tyrosines 1250 and 1251 with phenylalanine and histidine (amino acids present in the analogous positions in the insulin receptor), as well as phenylalanine 1310 replaced by tyrosine (IsY clones) to resemble the placement of tyrosine residues in the C-terminal domain of the insulin receptor. As a control for the IsY clones, a second mutant receptor was expressed with a substitution of phenylalanine 1310 with tyrosine only (DBY clones). Clones expressing IGF-IRs with the IsY substitutions had a significantly slower rate of growth compared with cells expressing an equivalent number of wild-type IGF-IRs (NWT). In contrast, the DBY clones showed relatively normal growth rates. Cells with wild-type IGF-IR demonstrated a transformed phenotype in soft agar assays. The IsY clones lost the transforming ability of the wild type IGF-IR, whereas DBY clones formed colonies. IGF-I-stimulated autophosphorylation of the IGF-IR and tyrosine phosphorylation of IRS-1 and SHC, known substrates in the IGF-IR signal transduction pathway, were studied. Mutated IGF-IRs (IsY and DBY) did not alter the IGF-I-induced tyrosine phosphorylation of these proteins. Furthermore, the mutated IGF-IRs did not alter Grb2 association with phosphorylated IRS-1 and SHC. IGF-I stimulation of Crk-II phosphorylation, a novel substrate of the IGF-IR, was similar in cells expressing mutated and wild-type IGF-IRs. IGF-I-induced activation of phosphatidylinositol (PI) 3'-kinase was equivalent in cells expressing either mutant or wild-type IGF-IRs. These data suggest that the IGF-IR mediates, at least in part, cellular proliferation and increased transforming ability through its C-terminal domain. The exact postreceptor signaling pathway(s) involved have yet to be fully elucidated.




This article has been cited by other articles:


Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
J. F. Kuemmerle
Occupation of {alpha}vbeta3-integrin by endogenous ligands modulates IGF-I receptor activation and proliferation of human intestinal smooth muscle
Am J Physiol Gastrointest Liver Physiol, June 1, 2006; 290(6): G1194 - G1202.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Leahy, A. Lyons, D. Krause, and R. O'Connor
Impaired Shc, Ras, and MAPK Activation but Normal Akt Activation in FL5.12 Cells Expressing an Insulin-like Growth Factor I Receptor Mutated at Tyrosines 1250 and 1251
J. Biol. Chem., April 30, 2004; 279(18): 18306 - 18313.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
S. R. Edmondson, S. P. Thumiger, G. A. Werther, and C. J. Wraight
Epidermal Homeostasis: The Role of the Growth Hormone and Insulin-Like Growth Factor Systems
Endocr. Rev., December 1, 2003; 24(6): 737 - 764.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Hurbin, L. Dubrez, J.-L. Coll, and M.-C. Favrot
Inhibition of Apoptosis by Amphiregulin via an Insulin-like Growth Factor-1 Receptor-dependent Pathway in Non-small Cell Lung Cancer Cell Lines
J. Biol. Chem., December 13, 2002; 277(51): 49127 - 49133.
[Abstract] [Full Text] [PDF]

Home page
 Cell Growth Differ.Home page
R. Rajah, K.-W. Lee, and P. Cohen
Insulin-like Growth Factor Binding Protein-3 Mediates Tumor Necrosis Factor-{alpha}-induced Apoptosis: Role of Bcl-2 Phosphorylation
Cell Growth Differ., April 1, 2002; 13(4): 163 - 171.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. B. Hassan and V. M. Macaulay
The insulin-like growth factor system as a therapeutic target in colorectal cancer
Ann. Onc., March 1, 2002; 13(3): 349 - 356.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J.-M. Ricort and M. Binoux
Insulin-Like Growth Factor (IGF) Binding Protein-3 Inhibits Type 1 IGF Receptor Activation Independently of Its IGF Binding Affinity
Endocrinology, January 1, 2001; 142(1): 108 - 113.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
P. Soni, M. Lakkis, M. N. Poy, M. A. Fernström, and S. M. Najjar
The Differential Effects of pp120 (Ceacam 1) on the Mitogenic Action of Insulin and Insulin-Like Growth Factor 1 Are Regulated by the Nonconserved Tyrosine 1316 in the Insulin Receptor
Mol. Cell. Biol., June 1, 2000; 20(11): 3896 - 3905.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
B. Urso, D. L. Cope, H. E. Kalloo-Hosein, A. C. Hayward, J. P. Whitehead, S. O'Rahilly, and K. Siddle
Differences in Signaling Properties of the Cytoplasmic Domains of the Insulin Receptor and Insulin-like Growth Factor Receptor in 3T3-L1 Adipocytes
J. Biol. Chem., October 22, 1999; 274(43): 30864 - 30873.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Y. Imai and D. R. Clemmons
Roles of Phosphatidylinositol 3-Kinase and Mitogen-Activated Protein Kinase Pathways in Stimulation of Vascular Smooth Muscle Cell Migration and Deoxyriboncleic Acid Synthesis by Insulin-Like Growth Factor-I
Endocrinology, September 1, 1999; 140(9): 4228 - 4235.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
A. A. Dandekar, B. J. Wallach, A. Barthel, and R. A. Roth
Comparison of the Signaling Abilities of the Cytoplasmic Domains of the Insulin Receptor and the Insulin Receptor-Related Receptor in 3T3-L1 Adipocytes
Endocrinology, August 1, 1998; 139(8): 3578 - 3584.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J.-L. Liu, V. A. Blakesley, J. S. Gutkind, and D. LeRoith
The Constitutively Active Mutant Galpha 13 Transforms Mouse Fibroblast Cells Deficient in Insulin-like Growth Factor-I Receptor
J. Biol. Chem., November 21, 1997; 272(47): 29438 - 29441.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Krause, A. Lyons, C. Fennelly, and R. O'Connor
Transient Activation of Jun N-terminal Kinases and Protection from Apoptosis by the Insulin-like Growth Factor I Receptor Can Be Suppressed by Dicumarol
J. Biol. Chem., May 25, 2001; 276(22): 19244 - 19252.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1997 by The Endocrine Society